PTC Inc. (PTC)
Bronstein, Gewirtz and Grossman, LLC sends a Class Action Lawsuit reminder to shareholder investors for PTC Therapeutics, Inc to Lead the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
PTC Stock Surges 30% in a Year: Will the Momentum Continue?
PTC's performance gains from solid momentum across the PLM and CAD business segments.
3 Robotics Stocks That Could Make Your Grandchildren Rich
The best robotics stocks to buy are those that will continue to attract investors who are trying to future-proof their portfolios. That's because the market could to grow 15.91% from $45.85 billion in 2024 to $95.93 billion in 2029.
1 Long-Term Growth Stock to Buy Hand Over Fist and 1 to Avoid
Automation is the future of manufacturing, and this company has a bright future, but its management needs to restore confidence in its guidance. This industrial software provider is about to start generating some serious cash flow.
PTC Inc. (PTC) Up 1.9% Since Last Earnings Report: Can It Continue?
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
PTC Stock Surges 41% in a Year: Will the Rally Continue?
PTC's performance gains from solid momentum across the PLM and CAD business segments.
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
PTC stock hit a nine-month high Monday after the European Commission decided against pulling its drug, Translarna, from the market. Translarna has a conditional approval in Europe to treat patients with a muscle-wasting disease known as Duchenne muscular dystrophy, or DMD. Twice — in September and January — the Committee for Medicinal Products for Human Use issued a negative opinion on the PTC Therapeutics (PTCT) drug. But following what PTC previously called "tremendous outcry from the patient and physician community," the European Commission has asked its committee to reexamine its opinion. And, so, "Translarna lives to fight another day," Leerink Partners analyst Joseph Schwartz said in a report to clients. It's rare for the European Commission to not adopt its committee's opinion, RBC Capital Markets analyst Brian Abrahams said in a client note. The news Monday increases the chances Translarna remains on the market in Europe and other jurisdictions, he said. But U.S. approval is still a wild card. "We believe the recent delay in EC action had made this outcome increasingly likely," he said. We "view this as a positive development, as it should improve cash flows, reduce capital raise needs and increase floor valuation into (Huntington's disease) data and (phenylketonuria) launch." On today's stock market, PTC stock rocketed 21.2% to 40.12. Shares launched into a profit-taking zone after breaking out of a cup base with a buy point at 32.91 earlier this month, according to MarketSurge. Following the European Commission's decision, PTC Therapeutics paused its guidance for 2024. The firm said it can't accurately forecast whether Translarna will remain on the market in Europe. But RBC's Abrahams says precedent suggests it will. The European Commission and CHMP had a similar back-and-forth over Uniqure's (QURE) now defunct gene therapy, Glybera. Glybera stayed on the market in Europe until Uniqure withdrew it due to commercial struggles in 2017. Abrahams kept his sector perform rating on PTC stock, but raised his price target to 39 from 29. He says the European Commission's decision wasn't a surprise given appeals from patients and doctors. Schwartz, the Leerink analyst, offered a similar view. "We generally see the European Medicines Agency as less easily influenced by patient advocacy groups than the Food and Drug Administration, but as we have noted in the past, DMD patient groups and DMD parents have a great deal of influence and shouldn't be discounted in the drug review and approval process," he said. He retained his market perform rating on PTC stock. Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin. YOU MAY ALSO LIKE: The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside? Get Timely Buy & Sell Alerts With IBD Leaderboard IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks Learn How To Time The Market With IBD's ETF Market Strategy
Vanguard Personalized Indexing Management LLC Has $1.15 Million Holdings in PTC Inc. (NASDAQ:PTC)
Vanguard Personalized Indexing Management LLC raised its position in shares of PTC Inc. (NASDAQ:PTC – Free Report) by 9.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,583 shares of the technology company’s stock after purchasing an additional 546 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in PTC were worth $1,152,000 as of its most recent SEC filing. Several other institutional investors have also made changes to their positions in the company. Metis Global Partners LLC lifted its position in shares of PTC by 24.4% in the third quarter. Metis Global Partners LLC now owns 5,783 shares of the technology company’s stock worth $819,000 after buying an additional 1,133 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in PTC by 25.2% in the 4th quarter. Handelsbanken Fonder AB now owns 25,300 shares of the technology company’s stock worth $4,426,000 after purchasing an additional 5,100 shares during the last quarter. USA Financial Formulas bought a new stake in PTC during the fourth quarter worth approximately $1,355,000. Silverberg Bernstein Capital Management LLC acquired a new position in PTC during the fourth quarter valued at approximately $9,647,000. Finally, Ballentine Partners LLC raised its position in shares of PTC by 786.0% in the fourth quarter. Ballentine Partners LLC now owns 15,336 shares of the technology company’s stock valued at $2,683,000 after purchasing an additional 13,605 shares during the period. 95.14% of the stock is currently owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades Several research firms recently issued reports on PTC. Barclays upped their price objective on shares of PTC from $198.00 to $215.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. Mizuho lowered their price target on PTC from $210.00 to $200.00 and set a “buy” rating on the stock in a research report on Thursday, May 2nd. Royal Bank of Canada reissued an “outperform” rating and set a $202.00 price objective on shares of PTC in a research report on Thursday, February 1st. StockNews.com raised PTC from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Finally, Rosenblatt Securities reiterated a “buy” rating and set a $195.00 price target on shares of PTC in a report on Friday, April 12th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, PTC presently has a consensus rating of “Moderate Buy” and a consensus target price of $200.64. View Our Latest Stock Report on PTC PTC Stock Up 0.0 % PTC opened at $184.22 on Monday. The company has a market capitalization of $22.05 billion, a P/E ratio of 77.08, a P/E/G ratio of 3.46 and a beta of 1.19. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.76 and a quick ratio of 0.76. The firm’s fifty day moving average price is $182.63 and its two-hundred day moving average price is $174.52. PTC Inc. has a fifty-two week low of $129.47 and a fifty-two week high of $194.24. About PTC (Free Report) PTC Inc operates as software company in the Americas, Europe, and the Asia Pacific. The company provides Windchill, a suite that manages all aspects of the product development lifecycle(PLM) that provides real-time information sharing, dynamic data visualization, collaborate across geographically distributed teams, and enabling manufacturers to elevate product development, manufacturing, and field service processes; ThingWorx, a platform for Industrial Internet of Things; ServiceMax, a field service management solutions enable companies to asset uptime with optimized in-person and remote service and technician productivity with mobile tools. Read More Five stocks we like better than PTC CD Calculator: Certificate of Deposit Calculator Canada Goose Flies Higher Driven By DTC Growth What is the Australian Securities Exchange (ASX) CVS Health Stock Has a Silver Lining Called Value Pros And Cons Of Monthly Dividend Stocks Magnificent 7 Still Magnificent as the Halfway Mark Approaches? Want to see what other hedge funds are holding PTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Inc. (NASDAQ:PTC – Free Report).
